{"id":67451,"date":"2026-06-23T21:56:12","date_gmt":"2026-06-23T16:26:12","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=67451"},"modified":"2026-06-23T21:56:14","modified_gmt":"2026-06-23T16:26:14","slug":"abruptly-stopping-cholesterol-lowering-medications-key-consequences","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/","title":{"rendered":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/3S6CDIpKX7k?si=1-eYWbZKSgpF9qGr\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">When a patient abruptly discontinues lipid-lowering therapy\u2014specifically statins\u2014the clinical outcome is dictated less by the gradual return of circulating cholesterol, and more by an acute <strong>pleiotropic rebound<\/strong> (a sudden loss of the drug&#8217;s lipid-independent, anti-inflammatory stabilizing effects on the vascular wall).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While a stable primary prevention patient with clear vessels might simply revert to their baseline lipid curve over a few weeks, an individual with established atherosclerotic disease enters an immediate, highly volatile window of plaque destabilization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Pathophysiology of the Rebound Overshoot<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">When intracellular statin concentrations drop to zero, the sudden unblocking of the mevalonate pathway triggers an overshoot in the production of downstream <strong>isoprenoids<\/strong> (lipid intermediates like farnesyl pyrophosphate that anchor signaling proteins to cell membranes). This sets off a rapid cascade of adverse vascular mechanics:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9345303\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9345303\/\">The Rho\/ROCK Activation Spike<\/a>:<\/strong> The sudden glut of isoprenoids causes an extreme over-activation of Rho-associated protein kinase (ROCK). This drives acute vascular smooth muscle contraction, spikes local reactive oxygen species, and suppresses <strong>endothelial nitric oxide synthase<\/strong> (the enzyme responsible for generating vasodilatory nitric oxide), instantly shifting the endothelium into a vasoconstrictive, pro-thrombotic state.<\/li>\n\n\n\n<li class=\"\"><strong>Enzymatic Cap Degradation:<\/strong> Within days of withdrawal, activated macrophages inside the atheroma ramp up the transcription of <strong>matrix metalloproteinases<\/strong> (enzymes that degrade collagen and the extracellular matrix). This rapidly thins the protective fibrous cap overlying the lipid core.<\/li>\n\n\n\n<li class=\"\"><strong>Platelet Hyper-reactivity:<\/strong> The sudden loss of statin-mediated tissue factor suppression prompts an uptick in circulating thromboxane A2 production. If the newly thinned fibrous cap suffers even a microscopic fissure, local rheology strongly favors immediate, occlusive thrombus propagation.<\/li>\n\n\n\n<li class=\"\"><strong>Receptor Re-equilibration:<\/strong> Systemically, the hepatic <strong>upregulation<\/strong> (the compensatory increase in cell-surface receptor density) of LDL receptors reverses within 14 to 21 days, returning circulating serum ApoB and LDL-C back to their pre-treatment baseline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical Risk Stratification<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Because this rebound phenomenon strikes the micro-environment of the vessel wall long before a standard serum lipid panel reflects the change, the clinical danger of stopping cold-turkey scales entirely with the patient&#8217;s underlying vascular anatomy:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Clinical Setting<\/strong><\/td><td><strong>Immediate Hazard (0\u201330 Days)<\/strong><\/td><td><strong>Long-Term Trajectory<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Stable Primary Prevention<\/strong><\/td><td>Negligible acute risk; serum lipids normalize within 2 to 4 weeks.<\/td><td>Gradual return to the patient&#8217;s baseline lifetime atherosclerotic risk curve.<\/td><\/tr><tr><td><strong>Stable Chronic CAD<\/strong><\/td><td>Subclinical spike in vascular inflammation and subtle endothelial dysfunction.<\/td><td>Accelerated expansion of existing necrotic cores and a higher 1-year MACE risk.<\/td><\/tr><tr><td><strong>Acute Coronary Syndrome (ACS)<\/strong><\/td><td>Severe risk of acute cap rupture, target lesion thrombosis, or fatal re-infarction.<\/td><td>Markedly elevated 90-day mortality (historically doubled compared to maintained therapy).<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Key Insight:<\/strong> The hazard of abrupt statin cessation in an unstable vessel is a classic biological paradox: the drug successfully quieted the inflammatory cross-talk of the atheroma, but withdrawing it acts as a cellular stress test, handing the inflammatory momentum right back to the vulnerable plaque.<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>References<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Giral P, Neumann A, Weill A, Coste J. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6855142\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6855142\/\">Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France<\/a>. Eur Heart J. 2019 Nov 14;40(43):3516-3525. doi: 10.1093\/eurheartj\/ehz458. PMID: 31362307; PMCID: PMC6855142.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Jeong HY, Lee SY, Kim SH, Kim J. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6855142\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6855142\/\">Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study<\/a>. Patient Prefer Adherence. 2020 Apr 5;14:717-724. doi: 10.2147\/PPA.S245324. PMID: 32308376; PMCID: PMC7147626.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lee SH, Kwon HS, Park YM, Ko SH, Choi YH, Yoon KH, Ahn YB. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3950197\/\" type=\"link\" id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3950197\/\">Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study<\/a>. Diabetes Metab J. 2014 Feb;38(1):64-73. doi: 10.4093\/dmj.2014.38.1.64. Epub 2014 Feb 19. PMID: 24627830; PMCID: PMC3950197.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>When a patient abruptly discontinues lipid-lowering therapy\u2014specifically statins\u2014the clinical outcome is dictated less by the gradual return of circulating cholesterol, and more by an acute pleiotropic rebound (a sudden loss of the drug&#8217;s lipid-independent, anti-inflammatory stabilizing effects on the vascular wall). While a stable primary prevention patient with clear vessels might simply revert to their [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":67455,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-67451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"When a patient abruptly discontinues lipid-lowering therapy\u2014specifically statins\u2014the clinical outcome is dictated less by the gradual return of circulating cholesterol, and more by an acute pleiotropic rebound (a sudden loss of the drug&#8217;s lipid-independent, anti-inflammatory stabilizing effects on the vascular wall). While a stable primary prevention patient with clear vessels might simply revert to their [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T16:26:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T16:26:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1278\" \/>\n\t<meta property=\"og:image:height\" content=\"719\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences\",\"datePublished\":\"2026-06-23T16:26:12+00:00\",\"dateModified\":\"2026-06-23T16:26:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/\",\"name\":\"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg\",\"datePublished\":\"2026-06-23T16:26:12+00:00\",\"dateModified\":\"2026-06-23T16:26:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg\",\"width\":1278,\"height\":719},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/","og_locale":"en_US","og_type":"article","og_title":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders","og_description":"When a patient abruptly discontinues lipid-lowering therapy\u2014specifically statins\u2014the clinical outcome is dictated less by the gradual return of circulating cholesterol, and more by an acute pleiotropic rebound (a sudden loss of the drug&#8217;s lipid-independent, anti-inflammatory stabilizing effects on the vascular wall). While a stable primary prevention patient with clear vessels might simply revert to their [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-06-23T16:26:12+00:00","article_modified_time":"2026-06-23T16:26:14+00:00","og_image":[{"width":1278,"height":719,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences","datePublished":"2026-06-23T16:26:12+00:00","dateModified":"2026-06-23T16:26:14+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/"},"wordCount":586,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/","url":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/","name":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg","datePublished":"2026-06-23T16:26:12+00:00","dateModified":"2026-06-23T16:26:14+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/06\/Abruptly-Stopping-Cholesterol-Lowering-Medications-Potwntrial-Key-Consequences.jpg","width":1278,"height":719},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/abruptly-stopping-cholesterol-lowering-medications-key-consequences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Abruptly Stopping Cholesterol Lowering Medications: Key Consequences"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=67451"}],"version-history":[{"count":4,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67451\/revisions"}],"predecessor-version":[{"id":67456,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67451\/revisions\/67456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/67455"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=67451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=67451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=67451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}